Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

A CXCR4-targeted site-specific antibody-drug conjugate.

Kularatne SA, Deshmukh V, Ma J, Tardif V, Lim RK, Pugh HM, Sun Y, Manibusan A, Sellers AJ, Barnett RS, Srinagesh S, Forsyth JS, Hassenpflug W, Tian F, Javahishvili T, Felding-Habermann B, Lawson BR, Kazane SA, Schultz PG.

Angew Chem Int Ed Engl. 2014 Oct 27;53(44):11863-7. doi: 10.1002/anie.201408103. Epub 2014 Sep 11.

2.

Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression.

Santidrian AF, Matsuno-Yagi A, Ritland M, Seo BB, LeBoeuf SE, Gay LJ, Yagi T, Felding-Habermann B.

J Clin Invest. 2013 Mar;123(3):1068-81. doi: 10.1172/JCI64264. Epub 2013 Feb 15.

3.

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.

Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, Lu Y, Tran H, Seller AJ, Biroc SL, Szydlik A, Pinkstaff JK, Tian F, Sinha SC, Felding-Habermann B, Smider VV, Schultz PG.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16101-6. doi: 10.1073/pnas.1211023109. Epub 2012 Sep 17.

4.

Platelets alter tumor cell attributes to propel metastasis: programming in transit.

Gay LJ, Felding-Habermann B.

Cancer Cell. 2011 Nov 15;20(5):553-4. doi: 10.1016/j.ccr.2011.11.001.

5.

Chemically programmed antibodies targeting multiple alpha(v) integrins and their effects on tumor-related functions in vitro.

Goswami RK, Bajjuri KM, Forsyth JS, Das S, Hassenpflug W, Huang ZZ, Lerner RA, Felding-Habermann B, Sinha SC.

Bioconjug Chem. 2011 Aug 17;22(8):1535-44. doi: 10.1021/bc2000879. Epub 2011 Aug 1.

6.

Selective formation of covalent protein heterodimers with an unnatural amino acid.

Hutchins BM, Kazane SA, Staflin K, Forsyth JS, Felding-Habermann B, Smider VV, Schultz PG.

Chem Biol. 2011 Mar 25;18(3):299-303. doi: 10.1016/j.chembiol.2011.01.006.

7.

Comparison of in vitro and in vivo approaches to studying brain colonization by breast cancer cells.

Lorger M, Lee H, Forsyth JS, Felding-Habermann B.

J Neurooncol. 2011 Sep;104(3):689-96. doi: 10.1007/s11060-011-0550-4. Epub 2011 Feb 27.

8.

Contribution of platelets to tumour metastasis.

Gay LJ, Felding-Habermann B.

Nat Rev Cancer. 2011 Feb;11(2):123-34. doi: 10.1038/nrc3004. Review.

PMID:
21258396
9.

Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids.

Hutchins BM, Kazane SA, Staflin K, Forsyth JS, Felding-Habermann B, Schultz PG, Smider VV.

J Mol Biol. 2011 Mar 4;406(4):595-603. doi: 10.1016/j.jmb.2011.01.011. Epub 2011 Jan 13.

10.

Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis.

Lorger M, Felding-Habermann B.

Am J Pathol. 2010 Jun;176(6):2958-71. doi: 10.2353/ajpath.2010.090838. Epub 2010 Apr 9.

11.

Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis.

Staflin K, Krueger JS, Hachmann J, Forsyth JS, Lorger M, Steiniger SC, Mee J, Pop C, Salvesen GS, Janda KD, Felding-Habermann B.

Clin Exp Metastasis. 2010 Apr;27(4):217-31. doi: 10.1007/s10585-010-9320-5. Epub 2010 Mar 12.

12.

An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation.

Wurdak H, Zhu S, Romero A, Lorger M, Watson J, Chiang CY, Zhang J, Natu VS, Lairson LL, Walker JR, Trussell CM, Harsh GR, Vogel H, Felding-Habermann B, Orth AP, Miraglia LJ, Rines DR, Skirboll SL, Schultz PG.

Cell Stem Cell. 2010 Jan 8;6(1):37-47. doi: 10.1016/j.stem.2009.11.002.

13.

Maintaining and engineering neural stem cells for delivery of genetically encoded therapy to brain tumors.

Katz J, Krueger J, Felding-Habermann B, Snyder EY.

Methods Mol Biol. 2009;568:249-59. doi: 10.1007/978-1-59745-280-9_16.

PMID:
19582432
14.

Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain.

Lorger M, Krueger JS, O'Neal M, Staflin K, Felding-Habermann B.

Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10666-71. doi: 10.1073/pnas.0903035106. Epub 2009 Jun 16.

15.

Multiple catalytic aldolase antibodies suitable for chemical programming.

Goswami RK, Huang ZZ, Forsyth JS, Felding-Habermann B, Sinha SC.

Bioorg Med Chem Lett. 2009 Jul 15;19(14):3821-4. doi: 10.1016/j.bmcl.2009.04.041. Epub 2009 Apr 18.

16.

Inhibition of tissue factor signaling suppresses tumor growth.

Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W.

Blood. 2008 Jan 1;111(1):190-9. Epub 2007 Sep 27.

17.

Platelet glycoprotein Ib alpha supports experimental lung metastasis.

Jain S, Zuka M, Liu J, Russell S, Dent J, Guerrero JA, Forsyth J, Maruszak B, Gartner TK, Felding-Habermann B, Ware J.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):9024-8. Epub 2007 May 9.

18.

Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery.

Liu Y, Steiniger SC, Kim Y, Kaufmann GF, Felding-Habermann B, Janda KD.

Mol Pharm. 2007 May-Jun;4(3):435-47. Epub 2007 Mar 21.

19.

The biology of metastasis to a sanctuary site.

Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS.

Clin Cancer Res. 2007 Mar 15;13(6):1656-62. Review.

20.

Adaptation of energy metabolism in breast cancer brain metastases.

Chen EI, Hewel J, Krueger JS, Tiraby C, Weber MR, Kralli A, Becker K, Yates JR 3rd, Felding-Habermann B.

Cancer Res. 2007 Feb 15;67(4):1472-86.

21.

Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand.

Kim Y, Lillo AM, Steiniger SC, Liu Y, Ballatore C, Anichini A, Mortarini R, Kaufmann GF, Zhou B, Felding-Habermann B, Janda KD.

Biochemistry. 2006 Aug 8;45(31):9434-44.

PMID:
16878978
22.

Large scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MudPIT).

Chen EI, Hewel J, Felding-Habermann B, Yates JR 3rd.

Mol Cell Proteomics. 2006 Jan;5(1):53-6. Epub 2005 Nov 4.

23.

Maspin alters the carcinoma proteome.

Chen EI, Florens L, Axelrod FT, Monosov E, Barbas CF 3rd, Yates JR 3rd, Felding-Habermann B, Smith JW.

FASEB J. 2005 Jul;19(9):1123-4. Epub 2005 Apr 27.

PMID:
15857880
24.

Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis.

Felding-Habermann B, Lerner RA, Lillo A, Zhuang S, Weber MR, Arrues S, Gao C, Mao S, Saven A, Janda KD.

Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17210-5. Epub 2004 Nov 24.

25.

A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalization and delivery of antitumor agents.

Lillo AM, Sun C, Gao C, Ditzel H, Parrish J, Gauss CM, Moss J, Felding-Habermann B, Wirsching P, Boger DL, Janda KD.

Chem Biol. 2004 Jul;11(7):897-906.

26.

Targeting tumor cell-platelet interaction in breast cancer metastasis.

Felding-Habermann B.

Pathophysiol Haemost Thromb. 2003;33 Suppl 1:56-8. No abstract available.

27.

Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells.

Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B.

Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9482-7. Epub 2003 Jul 21.

28.

Integrin adhesion receptors in tumor metastasis.

Felding-Habermann B.

Clin Exp Metastasis. 2003;20(3):203-13. Review.

PMID:
12741679
29.

Phage-display selection of a human single-chain fv antibody highly specific for melanoma and breast cancer cells using a chemoenzymatically synthesized G(M3)-carbohydrate antigen.

Lee KJ, Mao S, Sun C, Gao C, Blixt O, Arrues S, Hom LG, Kaufmann GF, Hoffman TZ, Coyle AR, Paulson J, Felding-Habermann B, Janda KD.

J Am Chem Soc. 2002 Oct 23;124(42):12439-46.

PMID:
12381184
30.

Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells.

Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M.

Clin Exp Metastasis. 2002;19(5):427-36.

PMID:
12198771
31.

Tumor cell-platelet interaction in metastatic disease.

Felding-Habermann B.

Haemostasis. 2001;31 Suppl 1:55-8. No abstract available.

PMID:
11990481
32.

Unique ability of integrin alpha(v)beta 3 to support tumor cell arrest under dynamic flow conditions.

Pilch J, Habermann R, Felding-Habermann B.

J Biol Chem. 2002 Jun 14;277(24):21930-8. Epub 2002 Apr 4.

33.

Integrin activation controls metastasis in human breast cancer.

Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM.

Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1853-8.

34.

Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.

Germer M, Kanse SM, Kirkegaard T, Kjøller L, Felding-Habermann B, Goodman S, Preissner KT.

Eur J Biochem. 1998 May 1;253(3):669-74.

35.

A single immunoglobulin-like domain of the human neural cell adhesion molecule L1 supports adhesion by multiple vascular and platelet integrins.

Felding-Habermann B, Silletti S, Mei F, Siu CH, Yip PM, Brooks PC, Cheresh DA, O'Toole TE, Ginsberg MH, Montgomery AM.

J Cell Biol. 1997 Dec 15;139(6):1567-81.

36.

Selective interaction of a conformationally-constrained Arg-Gly-Asp (RGD) motif with the integrin receptor alphavbeta3 expressed on human tumor cells.

Lanza P, Felding-Habermann B, Ruggeri ZM, Zanetti M, Billetta R.

Blood Cells Mol Dis. 1997 Aug;23(2):230-41.

PMID:
9268674
37.

Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.

Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, Di Filippo F, Giannarelli D, Temponi M, Ferrone S.

Cancer Res. 1997 Apr 15;57(8):1554-60.

38.

Molecular determinants of arg-gly-asp ligand specificity for beta3 integrins.

Kunicki TJ, Annis DS, Felding-Habermann B.

J Biol Chem. 1997 Feb 14;272(7):4103-7.

39.

Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow.

Felding-Habermann B, Habermann R, Saldívar E, Ruggeri ZM.

J Biol Chem. 1996 Mar 8;271(10):5892-900.

40.

Vitronectin and its receptors.

Felding-Habermann B, Cheresh DA.

Curr Opin Cell Biol. 1993 Oct;5(5):864-8. Review.

PMID:
7694604
41.

Involvement of integrin alpha V gene expression in human melanoma tumorigenicity.

Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA.

J Clin Invest. 1992 Jun;89(6):2018-22.

42.
43.

Glycolipid depletion using a ceramide analogue (PDMP) alters growth, adhesion, and membrane lipid organization in human A431 cells.

Barbour S, Edidin M, Felding-Habermann B, Taylor-Norton J, Radin NS, Fenderson BA.

J Cell Physiol. 1992 Mar;150(3):610-9.

PMID:
1537889
44.

Role of alpha V integrins and vitronectin in human melanoma cell growth.

Sanders LC, Felding-Habermann B, Mueller BM, Cheresh DA.

Cold Spring Harb Symp Quant Biol. 1992;57:233-40. No abstract available.

PMID:
1285050
45.

A ceramide analogue inhibits T cell proliferative response through inhibition of glycosphingolipid synthesis and enhancement of N,N-dimethylsphingosine synthesis.

Felding-Habermann B, Igarashi Y, Fenderson BA, Park LS, Radin NS, Inokuchi J, Strassmann G, Handa K, Hakomori S.

Biochemistry. 1990 Jul 3;29(26):6314-22.

PMID:
2207076
46.

Melanoma-associated gangliosides in the fish genus Xiphophorus.

Felding-Habermann B, Anders A, Dippold WG, Stallcup WB, Wiegandt H.

Cancer Res. 1988 Jun 15;48(12):3454-60.

47.

Carbohydrate analysis of chicken heart glycolipids.

Jennemann R, Felding-Habermann B, Geyer R, Stirm S, Wiegandt H.

Arch Biochem Biophys. 1987 Oct;258(1):240-7.

PMID:
3310900
48.

Glycosphingolipid biosynthesis in early chick embryos.

Felding-Habermann B, Jennemann R, Schmitt J, Wiegandt H.

Eur J Biochem. 1986 Nov 3;160(3):651-8.

Supplemental Content

Loading ...
Support Center